行情

NTRP

NTRP

Neurotrope
NASDAQ

实时行情|Nasdaq Last Sale

0.6720
+0.0147
+2.24%
盘后: 0.6700 -0.002 -0.30% 17:03 10/16 EDT
开盘
0.6648
昨收
0.6573
最高
0.6849
最低
0.6500
成交量
27.21万
成交额
--
52周最高
8.40
52周最低
0.6300
市值
875.05万
市盈率(TTM)
-0.4437
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTRP 新闻

  • 意大利内阁批准2020财年预算草案 修法打击偷漏税
  • 中国新闻网.2小时前
  • 韩国访日游客连续两个月大减
  • 新浪财经综合.2小时前
  • 欧盟峰会即将举行 英国“脱欧”还是“拖欧”?
  • 央视.2小时前
  • 欧洲理事会主席:英国脱欧协议有望17日获得批准
  • 中国新闻网.3小时前

更多

所属板块

软件
-1.68%
软件和IT服务
-0.60%

热门股票

名称
价格
涨跌幅

NTRP 简况

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.
展开

Webull提供Neurotrope Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。